Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Australia / NCT04649125
Recruiting Not applicable

Advanced Techniques For Single-fraction Palliative Radiotherapy Versus Standard Multi Fraction Radiation

NCT04649125 · tracked via the Priya Life Science Australia tracker
Sponsor
Royal North Shore Hospital
Phase
Not applicable
Started
2021-05-31
Last updated
2026-02-06

Condition(s) studied

Palliative Radiotherapy

Investigational drug(s) / intervention(s)

dose escalation

dose escalation: single fraction dose escalation to the tumour

Study summary

The aim of the study is to determine if single fraction dose escalated palliative radiotherapy results in a prolonged duration of benefit for patients otherwise suitable for Multifraction (5-10#) palliative radiation. The primary endpointis to determine the percentage of patients who have achieved a substantial benefit from palliative radiotherapy and have not redeveloped symptoms by 12 months post treatment

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Metastatic cancer * Recommended for 5-10 fractions palliative radiation * Patients with spinal cord compression are eligible for enrolment Exclusion Criteria: * Unwilling or unable to give informed consent * Patients who are recommended for single fraction palliative radiation

Primary outcome measure(s)

  • benefit from palliative radiotherapy — 9 months
    to determine the percentage of patients who have achieved a substantial benefit from palliative radiotherapy and have not redeveloped symptoms by 9 months post treatment

Trial sites (1)

FacilityCityRegionStatus
Royal North Shore Hospital Saint Leonards New South Wales Recruiting

More Royal North Shore Hospital trials in Australia

Pelvis Adaptive Radiotherapy (ART) Recruiting
Positioning of Esketamine Treatment in the Real-world Management of Depression Recruiting
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab Recruiting
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking Active, not recruiting
Continuous Monitoring of Prostate Position During Radiotherapy Active, not recruiting

Other trials for the same condition

Advanced Techniques for Single-fraction Palliative Radiotherapy Versus ASPIRE-single Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04649125 on ClinicalTrials.gov ↗ ← All trials in Australia